factors in leaf mitochondria reduce WA352 amounts, whereas WA352 accumulated in anther mitochondria, causing the male-specific mitochondrial defect. These results make this study a milestone in the understanding of the mechanism under lying plant CMS.
To directly test the role of OsCOX11 in male fertility, Luo et al. knocked down OsCOX11 expression specifically in the anther and found that this caused male sterility 11 . They also investigated the cellular effects that WA352 has on anther cells, finding abnormally high levels of reactive oxygen species (ROS) and cytochrome c around the outer membranes of mitochondria and in the cytosol, respectively, in anther tapetal cells expressing WA352. In addition, the presence of WA352 was associated with premature programmed cell death (PCD) of anther tapetal cells. Furthermore, a yeast cox11 mutant also had high ROS levels, cytochrome c release and PCD, indicating conservation of COX11 function.
Nuclear restorer genes
When CMS lines are used for hybrid seed production, the pollen donor must carry nuclear genes that can restore fertility so that the hybrid seed can be used for field planting. These nuclear genes are referred to as restorer of fertility (Rf) genes and counteract the effects of the mitochondrial sterility factors, protecting normal mitochondrial functions and male fertility 8, [12] [13] [14] . In WA rice, male fertility can be restored by either the Rf3 or Rf4 gene. Luo et al. 11 found that wild-type Rf4 caused a marked decrease in WA352 transcript levels, suggesting that Rf4 acts at the transcriptional or post-transcriptional level. Unlike plants with Rf4, Rf3-restored plants showed normal WA352 mRNA levels but lacked the WA352 protein, suggesting that Rf3 acts translationally or post-translationally. Therefore, Rf3 and Rf4 act via distinct mechanisms to inhibit WA352 and to ensure male fertility (Fig. 1, right) .
Several nuclear Rf genes have been analyzed molecularly, and they often encode members of the pentatricopeptide repeat (PPR) protein family 8, [12] [13] [14] . Several PPR proteins are known to localize to the mitochondria and reduce the expression of CMSrelated genes, using different mechanisms such as cleavage or degradation of CMS factor mRNA 8, 12 . Although the molecular nature of the Rf3 and Rf4 genes has not yet been determined, reduction of WA352 mRNA levels in the presence of Rf4 suggests that Rf4 might also degrade WA352 mRNA.
Evolutionary advantages
The WA532 gene was found in several wild rice accessions, suggesting that it originated in wild rice populations. The maintenance of this sterility gene in wild populations further supports the notion that the consequent male sterility may provide some selective advantage, at least under certain circumstances. The fact that WA352 inhibits mitochondrial function in the anther but not in other organs indicates that rice has evolved a mechanism to contain the detrimental effects of the WA352 gene product only to the male reproductive organ by having protective mechanisms in other organs. This further argues that male sterility can be adaptive under certain circumstances.
The common occurrence of CMS in plants is perhaps due to the very large mitochondrial genomes (of hundreds or more kilobases in length) that often rearrange 8 , with segregating male-sterile and male-fertile plants within the same population providing adaptive flexibility when population density and environmental resources change. In short, the genetic changes in both the mitochondrion and the nucleus make the plant either male sterile or fertile, rendering each genome competitive under different circumstances. Therefore, the 'battle between the genomes' discovered in this study is crucial for plant fertility and reproductive success, affecting crop production and natural population adaptability.
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Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, with an estimated incidence of 3.9 cases per 100,000 people in the United States and a median age of 72 years at the time of diagnosis 1 Whereas it is indolent in many patients, in others it is highly aggressive, resulting in rapid mortality. This clinical variability is likely due to the fact that CLL is genetically heterogeneous. Recent next-generation whole-genome and exome sequencing approaches have shown that CLLs possess strikingly complex genomic profiles, highlighted by multiple aberrations in chromosome structure and pathogenic mutations in at least seven distinct genetic pathways [2] [3] [4] . On page 526 of this issue, Carlos López-Otín and colleagues implicate telomere end protection as yet another genetic pathway perturbed in CLL 5 . They found that somatic mutations in the POT1 gene (encoding protection of telomere 1) are present in 3.5% of all CLL cases, occurring exclusively in the clinically aggressive CLL subtype with wild-type IGHV@. When they ranked CLL mutations by corrected frequency scores, which take into account gene size, the number of mutations found in the gene and codon composition, POT1 emerged as the second most frequently npg to telomeric ssDNA. Translocation of POT1 to an internal site, coupled with TPP1-mediated recruitment of telomerase, promotes telomere extension. Because POT1 OB-fold mutants cannot bind to telomeric ssDNA to repress telo merase access, telomerase is able to greatly lengthen telomeres (Fig. 1b) . As telomerase is limiting in CLL, POT1 mutations likely confer a survival advantage to B cells with wildtype IGHV@, maintaining their replicative potential and ability to generate additional subclones. This mechanism may also explain why POT1 mutations in CLL preferentially disrupt the OB fold. In contrast with these observations, critical telomere shortening resulting in end-to-end chromosome fusions has previously been documented in CLL, with very short telomere length being a negative predictor for disease survival 15 . Together, these results suggest the possibility of two distinct subtypes of CLL-one bearing POT1 mutations and elongated telomeres and the POT1 mutations promote CLL survival Despite the cytogenetic abnormalities observed in CLL cells and HT1080 cells expressing POT1 mutants, telomeres did not show evidence of a DNA damage response (DDR), which is a prominent characteristic of Pot1a-null cells 8, 9 . This unexpected result is likely due to the loading of wildtype POT1 onto telomeric ssDNA, thus preventing RPA binding and the initiation of CHK1-dependent DDR, which would be deleterious for cell survival 12 . In addition, POT1 mutants induced significant telomere elongation in HT1080 cells over many population doublings, with telomerase activity itself not upregulated. Insight into this unique mechanism of telo mere length extension comes from observations that the POT1-TPP1 heterodimer functions as both a positive and negative regulator of telomerase activity at telomeres 13, 14 . POT1 sequesters the 3′ singlestrand overhang, preventing telomerase access mutated gene. Clonal and subclonal analyses showed that POT1 mutations arise early, suggesting that they likely represent driver mutations in CLL 4 . POT1 is the first component of the telomere shelterin complex found to be mutated in human cancer, and this discovery further supports the hypothesis that telomere dysfunction results in the genomic rearrangements that are permissive for cancer initiation and progression 6 .
POT1 mutations induce chromosomal aberrations
Telomeres are specialized DNA-protein structures that cap the ends of all eukaryotic chromosomes and have important roles in genome stability. They are maintained by the enzyme telomerase and the shelterin complex, composed of the duplex telomere-binding proteins TRF1 and TRF2 and the single-stranded telomere-binding protein POT1 (ref. 7) . POT1 forms a heterodimer with TPP1, and TPP1 in turn tethers POT1 to TRF1 and TRF2-RAP1 through TIN2 (Fig. 1a) . POT1 contains two highly conserved oligonucleotide/ oligosaccharide-binding (OB) folds through which it binds to the 3′ terminus of the singlestranded G overhang. Remarkably, 19 of the 25 POT1 alterations in CLL clustered within both OB folds, and most affected phylogenetically conserved residues. In accord with a previous report 8 , POT1 OB-fold mutants could not bind telomeric single-stranded DNA (ssDNA) in vitro but were able to localize to telomeres, likely through recruitment by TPP1. CLL samples harboring POT1 mutations and the telomerase-positive HT1080 cell line expressing mutant POT1 all had chromosomal breaks and structural aberrations, indicative of loss of telomere capping function (Fig. 1b) . Importantly, these lesions were not observed when wild-type POT1 was overexpressed or in cells heterozygous for the mouse ortholog Pot1a 8, 9 , suggesting that these chromosomal aberrations arose as a consequence of mutation acquisition. Because all POT1 mutations in CLL are heterozygous, they likely have a dominant negative effect on the wild-type protein at telomeres. Analysis of the types of chromosomal aberrations shed light on the repair pathways disrupted by POT1 mutations in CLL. For example, the fusion of sister telomeres suggests the failure of the mutant POT1 to protect newly replicated telomere ends 10 , and the presence of fragile telomeres suggests that POT1 might have an unrecognized role in telomere replication 11 . These cytogenetic aberrations, coupled with chromosomal fusions generating dicentric chromosomes, are postulated to promote the genomic instability observed in CLL. In wild-type B cells, the shelterin complex, composed of TRF1, TRF2-RAP1, TIN2 and POT1-TPP1, protects telomeres and maintains chromosomal stability. The POT1-TPP1 complex functions to protect telomeres and to modulate telomerase access to telomeric 3′ ssDNA. TPP1 recruits telomerase to telomeres, promoting telomere extension, and POT1 competes with telomerase for access to the 3′ single-stranded telomeric overhang via its OB fold (pink box), preventing telomere extension. Red spheres on chromosomes represent telomeric DNA. (b) In B cells with wild-type IGHV@, mutations affecting the POT1 OB fold (denoted by the black dot in the pink box) abolish binding to telomeric 3′ ssDNA. Telomerase recruitment to telomeres is unrestrained, resulting in progressive telomere lengthening . In the presence of mutant POT1, chromosomal aberrations, including sister telomere fusions , fragile telomeres , chromosomal breaks  and chromosomal fusions with telomere signals at fusion sites , are prominent. This dysfunctional telomere-induced genomic instability, coupled with the acquisition of additional driver mutations, promotes progression to CLL. TERC RNA npg other with critically shortened telomeres with wild-type POT1 function.
Clinical directions
The discovery of POT1 mutations in CLL provides a compelling link between telomere dysfunction, genomic instability and human cancer, a connection previously documented in mouse models of telomere dysfunction and cancer 6 . Genomic instability due to POT1 mutations could contribute to the stepwise accumulation of mutational changes in favor of tumor initiation and progression, initially in a genetically heterogeneous cell population, then by clonal selection of more aggressive traits, including the ability to evade the impact of chemotherapeutic agents 4 . CLL disease progression is currently predicted by monitoring the mutation status of IGHV@, ZAP70 expression and the presence of recurrent cytogenetic aberrations 1 . Given the prevalence of POT1 mutations in the most aggressive form of this disease and the likelihood that these mutations confer survival advantages, monitoring a patient's POT1 mutational status is warranted. This information will be a first step toward the development of future personalized therapy to target CLL harboring POT1 mutations.
The identification of mutations in the CFH gene, encoding complement factor H, in children with atypical hemolytic-uremic syndrome (aHUS) led to the discovery of disease-causing alterations in several other complementregulatory proteins, underscoring the importance of uncontrolled activation of the complement pathway in this devastating disease 1,2 . On page 531of this issue, Richard Lifton and colleagues 3 report recessive loss-of-function mutations in DGKE as the cause of aHUS in a substantial proportion of pediatric cases presenting in the first year of life. All previously identified causes of aHUS are associated with abnormal activation of the complement system, which does not occur in individuals with DGKE-associated nephropathy, establishing for the first time an alternate pathophysiological mechanism for aHUS. devastating consequences for renal function and survival. In contrast to the more common diarrhea-associated HUS (D+HUS), which has a combined risk of 12% for end-stage renal disease (ESRD) or death, aHUS has a much higher risk of progression to ESRD (50%) or death (25%). Using exome sequencing, Lemaire et al. 3 identified recessive mutations in DGKE (encoding diacylglycerol kinase ε) that segregated with aHUS in nine unrelated kindreds, defining a new mendelian disorder. Twenty-two percent of the siblings of the affected probands also had aHUS and carried two affected alleles, demonstrating high penetrance. So far, efforts in diagnosing and treating aHUS have focused on proteins involved in regulating the alternative complement pathway. Indeed, causative mutations have been identified in the genes encoding complement factor H, complement factor B, complement factor I, complement component 3 (C3), CFHR1 and CFHR5, thrombomodulin and MCP 2, 4 . In addition, autoantibodies to complement factor H are associated with aHUS in 6-10% of cases 5, 6 . Disease-causing mutations result in uncontrolled activation of the complement pathway, with C3 deposition in kidney glomeruli, platelet aggregation, fibrin deposition and thrombus formation. Importantly, this form of disease may be successfully treated with eculizimab, a monoclonal antibody to complement component 5a (C5a), which inhibits the common complement activation pathway. Complement-mediated aHUS is also highly likely to recur after renal transplantation because of the systemic nature of the defect; eculizimab treatment for transplant recipients carrying complement gene mutations markedly reduces the risk of recurrence 7, 8 . The penetrance of disease varies and is highest in individuals with CFH or CFI mutations or with circulating autoantibodies to complement factor H. It is recognized that a secondary event, such as an infection, is often required to trigger episodes of aHUS 2 .
Beyond complement
The exciting findings of Lifton and colleagues 3 and an independent study by Attasanio and colleagues 9 identify a second mechanism leading to aHUS and thrombotic microangiopathy that is unrelated to complement activation. The cases reported by Lemaire et al. 3 exhibited some unique features that may alert physicians to possible mutations in DGKE. Disease presentation occurred early, typically before the age of 1 year, with multiple relapsing episodes, often progressing to ESRD by the second decade of life. DGKE mutations explained 27% of aHUS cases presenting in the first year of life and 50% of familial forms in this age group. In addition, three of the cases developed nephrotic syndrome within 3 to 5 years of diagnosis, characterized by heavy npg
